Skip to main content
رجوع
Watch Compare

Lantern Pharma Inc.

جودة البيانات: 83%
LTRN
NASDAQ Manufacturing Chemicals
KWD 2.33
▲ KWD 0.11 (4.96%)
6 months return
—
Momentum
Neutral
ROE
-154.86%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-154.86%
أقل من متوسط القطاع (-54.68%)
ROIC-128.40%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio3.33
Interest CoverageN/A

التقييم

PE (TTM|NTM)
-1.25 | -0.98
أعلى من متوسط القطاع (-1.50)
P/B Ratio2.23
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -15.68 M

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

2 محللين
Buy
+758.4%
upside to target
الحالي
KWD 2.33
Consensus Target
KWD 20.00
KWD 15.00
أدنى
KWD 25.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-0.98
ربحية السهم المستقبلية
-KWD 2.02
الإيرادات المقدّرة
0.0

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 0.36 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 0.42 -KWD 0.40 -KWD 0.39 -KWD 0.36 — —
Estimate -KWD 0.49 -KWD 0.49 -KWD 0.47 -KWD 0.46 -KWD 0.36 -KWD 0.38
المفاجأة +14.29% +17.53% +17.02% +21.74% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -154.86% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -17.12 M
ROE -154.86% ROA -110.28%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -15.68 M
ROIC -128.40% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 3.33
Debt / Equity N/A Current Ratio 3.33
Interest Coverage N/A Asset Turnover N/A
Working Capital 9.42 M Tangible Book Value 9.59 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1.25 · EV/EBITDA: N/A
P/E Ratio -1.25 Forward P/E -0.98
P/B Ratio 2.23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -73.32%
Market Cap 21.38 M Enterprise Value 12.99 M

Per Share

EPS: -1.57 · FCF/Share: -1.39
EPS (Diluted TTM) -1.57 Revenue / Share N/A
FCF / Share -1.39 OCF / Share -1.39
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 91.58% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 91.58%
SBC-Adj. FCF -16.31 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -17.12 M -20.78 M -15.96 M -14.26 M -12.36 M
EPS (Diluted) -1.57 -1.93 -1.47 — —
Gross Profit — — — — —
Operating Income -17.98 M -22.22 M -17.88 M -14.43 M —
EBITDA — — — — —
R&D Expenses 11.51 M 16.13 M 11.89 M 8.60 M 7.57 M
SG&A Expenses — — — — —
D&A 17,280.0 17,282.0 14,615.0 10,081.0 6,761.0
Interest Expense — — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 11.04 M 25.57 M 43.65 M 58.84 M 73.95 M
Total Liabilities 4.50 M 4.38 M 2.74 M 2.80 M 2.38 M
Shareholders' Equity 6.53 M 21.19 M 40.91 M 56.04 M 71.57 M
Total Debt — — — — —
Cash & Equivalents 4.42 M 7.51 M 21.94 M 37.20 M 51.52 M
Current Assets 10.80 M 25.25 M 43.34 M 58.72 M 72.72 M
Current Liabilities 4.50 M 4.33 M 2.68 M 2.80 M 2.33 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -1.3 -1.5
P/B 2.2 1.6
ROE % -154.9 -54.7
Net Margin % — -41.5
Rev Growth 5Y % — 1.7
D/E — 0.3

ETFs Holding This Stock
MEDX logo MEDX Horizon Kinetics Medical ETF
0.70% weight